Chronic Pain Procedures in Minnesota
This report examines the provision of chronic pain management services in Minnesota from 2010 through 2012. The report includes a description of the volume, geographic distribution, facility type, and provider type/specialty of the rendering provider.
Potentially Preventable Health Care Events in Minnesota
This report provides a baseline for the volume and associated spending of potentially preventable health care events in Minnesota in 2012.
Chronic Conditions in Minnesota: New Estimates of Prevalence, Cost and Geographic Variation for Insured Minnesotans, 2012
This report examines chronic disease prevalence and spending for Minnesota residents with health insurance in 2012, using Minnesota’s robust All Payers Claims Database (MN APCD). The report presents overall estimates of prevalence and spending for chronic conditions, considering approximately 125 distinct diseases. It also presents more detailed results for 10 select conditions. Estimates are prepared for the state overall, as well as at the county-level. Chronic Conditions in Minnesota - Supplemental Technical Information (PDF)
State-Based Risk Adjustment and Feasibility Study – Report to the Minnesota Legislature
This study, commissioned by the 2013 Minnesota Legislature, investigates the feasibility of state-based risk adjustment in Minnesota's individual and small group markets. In the study, the research team assessed the performance of the federal model with Minnesota data and performed statistical and actuarial modeling of a number of scenarios for Minnesota-based risk adjustment, including the effect of reinsurance.
Pharmaceutical Spending and Use in Minnesota: 2009-2013
This issue brief provides an overview of pharmaceutical spending and use trends in Minnesota from 2009 to 2013. This first analysis in a series of research initiatives distinguishes between prescription trends in retail pharmacy settings and medical settings (such as physicians’ offices and hospital outpatient clinics). The analysis looks at trends in the number of drug claims, total spending and spending per claim.